Seeking Alpha

Biomarin (BMRN) rockets 29% after saying that its GALNS drug met its main target in a Phase III...

Biomarin (BMRN) rockets 29% after saying that its GALNS drug met its main target in a Phase III trial of improving the walking ability of patients with the rare genetic disorder of Morquio A Syndrome. The drug is seen as the most important in BioMarin's pipeline, with the potential to double its revenue. (PR)
Comments (1)
  • Paulo Santos
    , contributor
    Comments (20486) | Send Message
     
    Weeee, that thing already discounts quite a bit of happiness in the future.
    5 Nov 2012, 08:27 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector